The impairment of CD3+ T lymphocytes in sentinel lymph node of high-risk cutaneous melanoma patients in stage IIB and IIC
Journal of Pathology and Translational Medicine · 15.07.2026 · 60 (4) · 422-435
DOI: 10.4132/jptm.2026.04.02 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pathology and Translational Medicine, erschienen am 15.07.2026. Verfasst von Emilija Filipović und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinic of Surgical Oncology, Institute of Oncology and Radiology of Serbia, Belgrade, Serbia. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Science, Technological Development and Innovation.
Abstract (Originalsprache)
Background
The sentinel lymph node (SLN) in melanoma is almost always the first site of metastasis and its histopathological assessment is essential for the determination of staging and clinical outcome. Furthermore, this procedure offers the investigation of the early immune response in SLN as melanoma-derived factors suppress the immunity in an early stage that may facilitate metastasis. A better understanding of the immunological changes in SLN may help in the therapeutic stimulation of melanoma immunity to prevent tumor metastasis.
Methods
SLN tissues without malignant cells from 74 cutaneous melanoma patients (stage I and II) were analyzed. By flow cytometry, we measured the percentage of natural killer cells, CD3+ T lymphocytes, and their expression of interferon-γ (IFN-γ) and inhibitory immune checkpoint molecules (ICMs), and the percentage of CD4+Foxp3+ regulatory T cells (Tregs).
Results
Melanoma patients with worse prognosis, in stage IIB–C, had decreased percentage of total CD3+ and CD3+CD8+ T lymphocytes, trend of IFN-γ decrease, increased inhibitory programmed cell death 1 and T cell immunoglobulin and mucin-domain containing 3 ICMs, and higher percentage of Tregs in their SLNs compared with stage I-IIA patients. Furthermore, patients with nodular melanoma had decreased CD3+CD8+ cells compared with patients with superficial spreading melanoma and together with patients with localization of primary tumor on extremities had an increase in the expression of analyzed ICMs.
Conclusions
This study provides new results of the impairment of immune response in SLN of cutaneous melanoma patients with high risk for metastasis and could help in the introduction of new immunotherapies that could restore immunity and prevent metastasis in SLN.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinic of Surgical Oncology, Institute of Oncology and Radiology of Serbia, Belgrade, Serbia.
- Department of Experimental Oncology, Institute of Oncology and Radiology of Serbia, Belgrade, Serbia. katarina.mirjacic@ncrc.ac.rs.
- Department of Pathology, Institute of Oncology and Radiology of Serbia, Belgrade, Serbia.
- Institute for Medical Statistics and Informatics, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
- School of Medicine, University of Belgrade, Belgrade, Serbia.
Förderung
- Ministry of Science, Technological Development and Innovation
Zitieren
APA
Filipović, E., Martinović, K. M., Živković, O., Milijić, N. M., Lazarević, A., Bukumirić, Z., Jevrić, M., & Žegarac, M. (2026). The impairment of CD3+ T lymphocytes in sentinel lymph node of high-risk cutaneous melanoma patients in stage IIB and IIC. Journal of Pathology and Translational Medicine, 60(4), 422-435. https://doi.org/10.4132/jptm.2026.04.02
Vancouver
Filipović E, Martinović KM, Živković O, Milijić NM, Lazarević A, Bukumirić Z, et al. The impairment of CD3+ T lymphocytes in sentinel lymph node of high-risk cutaneous melanoma patients in stage IIB and IIC. Journal of Pathology and Translational Medicine. 2026;60(4):422-435. doi:10.4132/jptm.2026.04.02
BibTeX
@article{Filipovi2026,
author = {Filipović, Emilija and Martinović, Katarina Mirjačić and Živković, Ognjen and Milijić, Nataša Medić and Lazarević, Ana and Bukumirić, Zoran and Jevrić, Marko and Žegarac, Milan},
title = {The impairment of CD3+ T lymphocytes in sentinel lymph node of high-risk cutaneous melanoma patients in stage IIB and IIC},
journal = {Journal of Pathology and Translational Medicine},
year = {2026},
volume = {60},
number = {4},
pages = {422--435},
doi = {10.4132/jptm.2026.04.02}
}
EUVIMED